- Reuters•5 days ago
EU antitrust regulators said on Wednesday they had cleared generic drugmaker Mylan's planned cash-and-stock purchase of Sweden's Meda subject to it selling certain assets. Reuters last week reported that Mylan was set to get the green light after offering concessions. The Commission said it had identified 15 markets where it had competition concerns, because of the strong position of the two companies and the lack of sufficient alternatives.
- Bloomberg•3 months ago
Mylan NV’s chief executive officer says that the drug industry’s pain over the last few months will eventually be her company’s gain.
|Day's Range||0.00 - 0.00|
|Avg Vol (3m)||684,389|
As of 11:29 AM EDT. Market closed.